0001490953-26-000003.txt : 20260904 0001490953-26-000003.hdr.sgml : 20260904 20260904111854 ACCESSION NUMBER: 0001490953-26-000003 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: Rule 506(b) provides a "safer harbor" for a private offering FILED AS OF DATE: 20260904 DATE AS OF CHANGE: 20260904 EFFECTIVENESS DATE: 20260904 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Immunophotonics, Inc. CENTRAL INDEX KEY: 0001490953 ORGANIZATION NAME: EIN: 264471225 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-596476 FILM NUMBER: 261360836 BUSINESS ADDRESS: STREET 1: 4320 FOREST PARK AVENUE, #303 (BAL) CITY: ST. LOUIS STATE: MO ZIP: 63108 BUSINESS PHONE: 636-675-6161 MAIL ADDRESS: STREET 1: 4320 FOREST PARK AVENUE, #303 (BAL) CITY: ST. LOUIS STATE: MO ZIP: 63108 FORMER COMPANY: FORMER CONFORMED NAME: ImmunoPhotonics, Inc. DATE OF NAME CHANGE: 20100503 D 1 primary_doc.xml X0708 D LIVE 0001490953 Immunophotonics, Inc. 4340 Duncan Ave., Suite 212 ST. LOUIS MO MISSOURI 63110 314-501-1919 DELAWARE ImmunoPhotonics, Inc. Corporation true Alexander Michael Hurst 4340 Duncan Ave., Suite 212 St. Louis MO MISSOURI 63110 Executive Officer Robert H. Arch 4340 Duncan Ave., Suite 212 St. Louis MO MISSOURI 63110 Executive Officer Miguel M. Zubizarreta 4340 Duncan Ave., Suite 212 St. Louis MO MISSOURI 63110 Director Luciano Alleruzzo 4340 Duncan Ave., Suite 212 St. Louis MO MISSOURI 63110 Director Promoter Jonathan Knowles 4340 Duncan Ave., Suite 212 St. Louis, MO, USA MO MISSOURI 63110 Director Wei Chen 4340 Duncan Ave., Suite 212 St. Louis MO MISSOURI 63110 Director Promoter Jacqueline Hess 4340 Duncan Ave., Suite 212 St. Louis MO MISSOURI 63110 Director Richard Levenson 4340 Duncan Ave., Suite 212 St. Louis MO MISSOURI 63110 Director Pharmaceuticals Decline to Disclose 06b false 2025-07-14 true true false 100000 Indefinite 10147612 Indefinite Raised using rolling closings with majority in a tranche that closed in late August 2026. true 4 45 0 0 0 A portion of the gross proceeds will be used for general working capital, a portion of which will include normal salary payments to executive officers. An estimate of such amount is unknown at this time. false Immunophotonics, Inc. Alexander Hurst Alexander Hurst Chief Corporate Officer, General Counsel, & Corp. Secretary 2026-09-04